A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir

Clinical Pharmacology and Therapeutics

Volumn 87, Issue 6, 2010, Pages 735-742

  Dumond, J B ^a   Vourvahis, M ^a   Rezk, N L ^a   Patterson, K B ^b   Tien, H C ^a   White, N ^a   Jennings, S H ^a   Choi, S O ^a   Li, J ^a   Wagner, M J ^c   La Beck, N M ^a   Drulak, M ^d   Sabo, J P ^d   Castles, M A ^d   MacGregor, T R ^d   Kashuba, A D M ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c University of North Carolina   (United States)

^d BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYOMEPRAZOLE; CAFFEINE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; DEXTROMETHORPHAN; DEXTRORPHAN; DIGOXIN; DRUG METABOLITE; GLYCOPROTEIN P; MIDAZOLAM; OMEPRAZOLE; RITONAVIR PLUS TIPRANAVIR; UNCLASSIFIED DRUG; VITAMIN K GROUP; WARFARIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BRAIN HEMORRHAGE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG WITHDRAWAL; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; EVENING DOSAGE; FEMALE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INTERNATIONAL NORMALIZED RATIO; MALE; MIGRAINE; MORNING DOSAGE; MULTIPLE DRUG DOSE; NAUSEA AND VOMITING; PARTIAL THROMBOPLASTIN TIME; PATIENT COMPLIANCE; PHARMACOGENOMICS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; STEADY STATE; WITHDRAWAL SYNDROME;

ADULT; ANTI-HIV AGENTS; AREA UNDER CURVE; CYTOCHROME P-450 ENZYME SYSTEM; DRUG COMBINATIONS; DRUG INTERACTIONS; ENZYME INDUCTION; ENZYME INHIBITORS; FEMALE; GENOTYPE; HIV PROTEASE INHIBITORS; HUMANS; INTESTINES; LIVER; MALE; P-GLYCOPROTEIN; PHARMACEUTICAL PREPARATIONS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PYRIDINES; PYRONES; RITONAVIR; YOUNG ADULT;

EID: 77952584975     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.253     Document Type: Article

References (28)

1. Derks, M., Fowler, S. & Kuhlmann, O. In vitro and in vivo assessment of the efect of dalcetrapib on a panel of CYP substrates. Curr. Med. Res. Opin. 25, 891-902 (2009)
2. johnson, B.M. et al. Evaluation of the drug interaction potential of aplaviroc, a novel human immunodefciency virus entry inhibitor, using a modifed cooperstown 5 + 1 cocktail. J. Clin. Pharmacol. 46, 577-587 (2006).
3. Lim, M.L. et al. Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction. J. Acquir. Immune Defc. Syndr. 36, 1034-1040 (2004).
4. Shelepova, T. et al. Efect of a triphasic oral contraceptive on drug-metabolizing enzyme activity as measured by the validated Cooperstown 5+1 cocktail. J. Clin. Pharmacol. 45, 1413-1421 (2005).
5. Yeh, R.F. et al. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J. Acquir. Immune Defc. Syndr. 42, 52-60 (2006).
6. Chainuvati, S. et al. Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail". Clin. Pharmacol. Ther. 74, 437-447 (2003).
7. Berggren, S. et al. Gene and protein expression of P-glycoprotein, MRP1, MRP2, and CYP3A4 in the small and large human intestine. Mol. Pharm. 4, 252-257 (2007).
8. Igel, S. et al. Increased absorption of digoxin from the human jejunum due to inhibition of intestinal transporter-mediated efux. Clin. Pharmacokinet. 46, 777-785 (2007).
9. Boehringer Ingelheim Pharmaceuticals. Tipranavir: Antiviral Drugs Advisory Committee (AVDAC) Briefng Document. NDA 21-814 (Ridgefeld, CT, 2005) http://www.fda.gov/ohrms/DOCKETS/ac/05/briefng/2005-4139b1-02-boehringer.pdf.
10. Walmsley, S. et al. Pharmacokinetics, safety, and efcacy of tipranavir boosted with ritonavir alone or in combination with other boosted protease inhibitors as part of optimized combination antiretroviral therapy in highly treatment-experienced patients (BI study 1182.51). J. Acquir. Immune Defc. Syndr. 47, 429-440 (2008).
11. Norvir [package insert]. North Chicago, IL: Abbott Laboratories, 2006.
12. Rasmussen, B.B. & Brøsen, K. Determination of urinary metabolites of cafeine for the assessment of cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activity in humans. Ther. Drug Monit. 18, 254-262 (1996).
13. Grant, D.M., Tang, B.K. & Kalow, W. Variability in cafeine metabolism. Clin. Pharmacol. Ther. 33, 591-602 (1983).
14. Fuhr, U. et al. Evaluation of cafeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations. Pharmacogenetics 6, 159-176 (1996).
15. Hughes, C.A., Freitas, A. & Miedzinski, L.j. Interaction between lopinavir/ritonavir and warfarin. CMAJ 177, 357-359 (2007).
16. Knoell, K.R., Young, T.M. & Cousins, E.S. Potential interaction involving warfarin and ritonavir. Ann. Pharmacother. 32, 1299-1302 (1998).
17. Newshan, G. & Tsang, P. Ritonavir and warfarin interaction. AIDS 13, 1788-1789 (1999).
18. Lexiva [package insert]. Research Triangle Park, NC: GlaxoSmithKline, 2007.
19. Paine, M.F., Hart, H.L., Ludington, S.S., Haining, R.L., Rettie, A.E. & Zeldin, D.C. The human intestinal cytochrome P450 "pie". Drug Metab. Dispos. 34, 880-886 (2006).
20. Invirase [package insert]. Nutley, Nj: Roche Laboratories, 2007.
21. Sabo, j. et al. The pharmacokinetic interaction between atazanavir/ritonavir (ATV/r) and steady-state tipranavir/ritonavir (TPV/r) in healthy volunteers. 7th International Workshop on Clinical Pharmacology of HIV Therapy, Lisbon, Portugal 20-22 April 2006.
22. Ding, R. et al. Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. Clin. Pharmacol. Ther. 76, 73-84 (2004).
23. Wyen, C. et al. P-glycoprotein is inhibited by lopinavir and low-dose ritonavir in HIV-infected patients and in healthy men. 8th International Congress on Drug Therapy in HIV Infection, Glasgow, UK, 12-16 November 2006.
24. Vormfelde, S.V. et al. Relative impact of genotype and enzyme induction on the metabolic capacity of CYP2C9 in healthy volunteers. Clin. Pharmacol. Ther. 86, 54-61 (2009).
25. US Food and Drug Administration. FDA Guidance for Industry: Drug Interaction Studies\Study Design, Data Analysis, and Implications for Dosing and Labeling. Draft guidance (Rockville, MD, 2006)
26. Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events http://www.ucdmc.ucdavis.edu/clinicaltrials/documents/DAIDS- AE-GradingTable-FinalDec2004.pdf (2004).
27. Food and Drug Administration. Guidance for Industry: Bioanalytical Method Validation (Rockville, MD, 2001).
28. Dumaual, C. et al. Comprehensive assessment of metabolic enzyme and transporter genes using the Afymetrix Targeted Genotyping System. Pharmacogenomics 8, 293-305 (2007).